Last reviewed · How we verify
Lamivudine (LAM)
Lamivudine (LAM) is a Nucleoside reverse transcriptase inhibitor (NRTI) Small molecule drug developed by Hoffmann-La Roche. It is currently FDA-approved for HIV-1 infection (in combination with other antiretroviral agents), Chronic hepatitis B infection.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV and hepatitis B virus replication by inhibiting the reverse transcriptase enzyme.
Lamivudine is a nucleoside reverse transcriptase inhibitor (NRTI) that blocks HIV and hepatitis B virus replication by inhibiting the reverse transcriptase enzyme. Used for HIV-1 infection (in combination with other antiretroviral agents), Chronic hepatitis B infection.
At a glance
| Generic name | Lamivudine (LAM) |
|---|---|
| Sponsor | Hoffmann-La Roche |
| Drug class | Nucleoside reverse transcriptase inhibitor (NRTI) |
| Target | HIV reverse transcriptase; Hepatitis B virus reverse transcriptase |
| Modality | Small molecule |
| Therapeutic area | Infectious Disease |
| Phase | FDA-approved |
Mechanism of action
Lamivudine is a cytidine analog that gets phosphorylated intracellularly and incorporated into the viral DNA chain during reverse transcription, causing chain termination. This prevents the conversion of viral RNA to DNA, thereby blocking HIV and HBV replication. It is commonly used as part of combination antiretroviral therapy (ART) for HIV and as monotherapy or combination therapy for chronic hepatitis B.
Approved indications
- HIV-1 infection (in combination with other antiretroviral agents)
- Chronic hepatitis B infection
Common side effects
- Headache
- Nausea
- Fatigue
- Diarrhea
- Pancreatitis
- Peripheral neuropathy
- Lactic acidosis
Key clinical trials
- Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment
- Study of Cobicistat-Boosted Atazanavir (ATV/co), Cobicistat-Boosted Darunavir (DRV/co) and Emtricitabine/Tenofovir Alafenamide (F/TAF) in Children With HIV (PHASE2, PHASE3)
- Study to Evaluate the Efficacy, Safety, and Tolerability of Long-acting Intramuscular Cabotegravir and Rilpivirine for Maintenance of Virologic Suppression Following Switch From an Integrase Inhibitor in HIV-1 Infected Therapy Naive Participants (PHASE3)
- A Randomized Clinical Trial to Evaluate Solutions for the Management of Virologic Failure on TLD in Sub-Saharan Africa (NA)
- A Study to Provide Continued Access to Study Drug to Children and Adolescents Who Have Completed Clinical Studies Involving Gilead HIV Treatments (PHASE4)
- A Phase 2b Study Evaluating Oral VH4524184 Regimens in Treatment Naïve Persons With HIV-1 (INNOVATE Study) (PHASE2)
- A Study to Evaluate the Efficacy, Safety, Participant Choice and Preference of an Oral Once-daily Regimen or a Long-acting Injectable Regimen Every Two Months for Treatment of Human Immunodeficiency Virus (HIV-1) in Adults Who Have Not Previously Taken Antiretroviral Therapy (PHASE3)
- Entecavir Resistance-Associated Mutations in Chronic HBV Patients in Turkey (STREAM Study)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- Lamivudine (LAM) CI brief — competitive landscape report
- Lamivudine (LAM) updates RSS · CI watch RSS
- Hoffmann-La Roche portfolio CI
Frequently asked questions about Lamivudine (LAM)
What is Lamivudine (LAM)?
How does Lamivudine (LAM) work?
What is Lamivudine (LAM) used for?
Who makes Lamivudine (LAM)?
What drug class is Lamivudine (LAM) in?
What development phase is Lamivudine (LAM) in?
What are the side effects of Lamivudine (LAM)?
What does Lamivudine (LAM) target?
Related
- Drug class: All Nucleoside reverse transcriptase inhibitor (NRTI) drugs
- Target: All drugs targeting HIV reverse transcriptase; Hepatitis B virus reverse transcriptase
- Manufacturer: Hoffmann-La Roche — full pipeline
- Therapeutic area: All drugs in Infectious Disease
- Indication: Drugs for HIV-1 infection (in combination with other antiretroviral agents)
- Indication: Drugs for Chronic hepatitis B infection
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing